NYSE · CIK 0001582554
MTNB Matinas BioPharma Holdings, Inc.
Insider trading from SEC Form 4. Last filing May 2, 2025.
Matinas BioPharma Holdings, Inc. (MTNB) has 8 SEC Form 4 filings on file from 8 insiders, the latest filed on May 2, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Matinas BioPharma Holdings, Inc., scored.
Transactions
Every row filed, 11 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 30, 2025 | An Evelyn D director | AGrant or award Stock Option (right to Buy)derivative | +11,600 | $0.00 | $0 | 11,600 | May 2, 2025 |
| Apr 30, 2025 | Jerome D Jabbour President and CEO | AGrant or award Stock Option (right to Buy)derivative | +70,100 | $0.00 | $0 | 70,100 | May 2, 2025 |
| Apr 30, 2025 | Keith Murphy director | AGrant or award Stock Option (right to Buy)derivative | +11,600 | $0.00 | $0 | 11,600 | May 2, 2025 |
| Apr 30, 2025 | Edward Neugeboren director | AGrant or award Stock Option (right to Buy)derivative | +11,600 | $0.00 | $0 | 11,600 | May 2, 2025 |
| Apr 30, 2025 | Robin L Smith director | AGrant or award Stock Option (right to Buy)derivative | +11,600 | $0.00 | $0 | 11,600 | May 2, 2025 |
| Apr 8, 2025 | Pembroke & Partners LLC owner | POpen-market purchase Series C Convertible Preferred Stockderivative | +492 | $1,000.00 | $492k | 984 | Apr 10, 2025 |
| Apr 8, 2025 | Sanitam Partners LLC owner | POpen-market purchase Series C Convertible Preferred Stockderivative | +703 | $1,000.00 | $703k | 1,406 | Apr 10, 2025 |
| Apr 8, 2025 | Robert J Eide owner | POpen-market purchase Series C Convertible Preferred Stockderivativeindirect: R. Eide as managing partner for Pembroke | +492 | $1,000.00 | $492k | 984 | Apr 10, 2025 |
| Apr 8, 2025 | Pembroke & Partners LLC owner | POpen-market purchase Warrantsderivative | +1,679,182 | - | - | 3,358,364 | Apr 10, 2025 |
| Apr 8, 2025 | Sanitam Partners LLC owner | POpen-market purchase Warrantsderivative | +2,399,318 | - | - | 4,798,636 | Apr 10, 2025 |
| Apr 8, 2025 | Robert J Eide owner | POpen-market purchase Warrantsderivativeindirect: R. Eide as managing partner for Pembroke | +1,679,182 | - | - | 3,358,364 | Apr 10, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- An Evelyn Ddirector
- Robert J Eideowner
- Jerome D JabbourPresident and CEO
- Keith Murphydirector, chair, officer
- Edward Neugeborendirector
- Pembroke & Partners LLCowner
- Sanitam Partners LLCowner
- Robin L Smithdirector
Questions about MTNB
Answered from the filings on this page, as of the latest one.
Are insiders buying MTNB?
No. In the last 90 days no insider at Matinas BioPharma Holdings, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MTNB on the open market?
No open-market trade has been scored at Matinas BioPharma Holdings, Inc.. The latest Form 4 on file was filed on May 2, 2025 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Matinas BioPharma Holdings, Inc.?
8 people have filed a Form 4 at Matinas BioPharma Holdings, Inc., among them An Evelyn D (director), Robert J Eide (10% owner), Jerome D Jabbour (President and CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.